<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01392768</url>
  </required_header>
  <id_info>
    <org_study_id>ACH-LPT-03(09/10)</org_study_id>
    <nct_id>NCT01392768</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Levetiracetam in Partial Seizures Control, With or Without Secondary Generalization</brief_title>
  <acronym>Mozart</acronym>
  <official_title>A Double-blind, Phase III, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Levetiracetam as Adjunctive Therapy, in Partial Seizures Control Associated With Refractory Focal Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ache Laboratorios Farmaceuticos S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ache Laboratorios Farmaceuticos S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether levetiracetam as adjunctive therapy is
      effective in the treatment of partial seizures, with or without secondary generalization,
      associated with refractory focal epilepsy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Partial onset seizure frequency per week.</measure>
    <time_frame>From baseline to week 24</time_frame>
    <description>Collection of seizure count throughout the whole study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety descriptive about occurence of adverse events, evaluation of results of clinical/physical examination and ECG and laboratory tests results.</measure>
    <time_frame>From baseline to week 30</time_frame>
    <description>Collection of safety data throughout the whole study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of response between the groups of treatment. (Responders defined as number of patients with at least 50% reduction in the number of weekly partial seizures)</measure>
    <time_frame>From baseline to week 24</time_frame>
    <description>Comparative between baseline and treatment periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage reduction from baseline in partial seizure frequency of days a week.</measure>
    <time_frame>From baseline to week 24</time_frame>
    <description>Comparative between baseline and treatment periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of response between the groups of treatment. (Responders defined as number of subjects with at least 50% reduction in the number of days per week with partial seizures)</measure>
    <time_frame>From baseline to week 24</time_frame>
    <description>Comparative between baseline and treatment periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion between the groups of treatment without any kind of seizures. (seizure free)</measure>
    <time_frame>12 weeks after the titration period (period with stable regimen of the drug)</time_frame>
    <description>During the evaluation period of treatment, without the titration period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Epilepsy</condition>
  <condition>Partial Seizures</condition>
  <arm_group>
    <arm_group_label>Levetiracetam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <description>Oral solution (Each mL contains 100mg of levetiracetam) or immediate-release tablets (Tablets containing 500mg or 1000mg of levetiracetam)</description>
    <arm_group_label>Levetiracetam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, properly standardized to suit the characteristics of each dosage form (oral solution and tablets) of levetiracetam</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both sexes, aged between 04 and 65 years, remaining the feasibility of a
             legal guardian in accordance with need, able to understand and provide written
             informed consent and able to allow compliance at the treatment and the requirements of
             the protocol;

          -  Patient´s weight ≥ 20kg;

          -  Consistent diagnosis of refractory focal epilepsy, with or without secondary
             generalization;

          -  Patient with onset of seizures for at least 02 years preceding the screening visit;

          -  Presence at least 12 partial seizures during the 03 months preceding the screening
             visit (04 seizures per month);

               -  Only seizures that generate motor manifestation will be recorded in this study.

          -  Absence of brain injury progressive or expansive, previously documented by CT scan,
             MRI or other imaging test applicable (in the last 05 years;

          -  Patient with electroencephalogram performed up to 02 years before this visit;

          -  Subject with stable regimen (minimum of 01 month) from one to three antiepileptic
             drugs.

               -  Vagus nerve stimulation for 04 weeks prior to V1, or use of benzodiazepines for
                  more than 07 consecutive days will be considered as concomitant epileptic drugs)

        Exclusion Criteria:

          -  Patients with:

               -  Seizures of non epileptic origin;

               -  Pseudoseizures;

               -  Seizures occurring in clustered patterns (03 or more seizures in 30 minutes), in
                  the 03 months preceding the screening visit (V1);

               -  History of status epilepticus while taking antiepileptic drugs during the 03
                  months that preceding the screening visit (V1).

          -  Epileptic syndromes that occurs with cognitive deficits or secondary epilepsy evolving
             from some brain disease;

          -  History of schizophrenia or suicide attempt;

          -  Patients with psychiatric ill ongoing;

          -  Presence of severe mental retardation of any etiology;

          -  Previous exposure to levetiracetam;

          -  Women of childbearing age who had tested positive for pregnancy, or who do not use
             acceptable contraceptive method, or do not agree to practice reliable contraception
             during the study;

          -  Woman in pregnancy or lactation period;

          -  Diagnosis of renal or hepatic failure;

          -  Patients with genetic syndromes;

          -  Patient that is taking any prohibited medication (Item 9.3);

          -  Participation in last one year of clinical protocols, unless it can be direct benefit
             to subject;

          -  Relatives of sponsor´s or study site´s employee;

          -  Current evidence of clinically significant diseases: hematopoietic, gastrointestinal,
             cardiovascular, hepatic, renal, neurological, endocrine, psychiatric, autoimmune,
             pulmonary, or another disease that block the subject participation;

          -  Any finding of clinical observation (anamnesis and physical exam) laboratory
             abnormality (e.g., blood glucose, blood count), disease (for example, liver,
             cardiovascular system, lung) or therapy that, in opinion of the investigator, may
             endanger the subject or interfere with the endpoints of study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elza M Yacubian</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of São Paulo</affiliation>
  </overall_official>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2011</study_first_submitted>
  <study_first_submitted_qc>July 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2011</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>Partial</keyword>
  <keyword>Seizures</keyword>
  <keyword>Adjunctive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

